Family grateful for end-of-life care at Rockhampton's Fitzroy Community Hospice
His family did not want the 85-year-old to die in hospital, but knew bringing him home could be overwhelming and complicated.
"His ailments were complex, and it was very daunting to think about caring for him ourselves," Neil's daughter-in-law Toni Robinson said.
A friend suggested hospice care, and it ended up being the solution Neil's family was looking for.
"My friend's father was cared for at a hospice, and it was such a comfort to his family," she said.
Neil spent his last week at the Fitzroy Community Hospice, the only end-of-life care option outside hospitals or aged care homes between Gympie and Townsville, a stretch of nearly 1,000 kilometres.
The community not-for-profit hospice opened its doors in June 2024 to provide better end-of-life care in central Queensland.
The second stage of the project opened last month to expand its capacity.
The new rooms have more space for families, which means people coming from outside the area to be with loved ones have somewhere to stay.
"Some people have confused us with aged care, but those we care for are referred to us through medical practitioners and nurse practitioners," chief executive officer Beth Thomas said.
Funding is provided through an agreement with Queensland Health for several public beds and private health insurers, as well as ongoing fundraising.
Ms Thomas said the organisation's executives worked with local GPs and the community to get the word out about the specifics of end-of-life care.
"It's about taking the burden of care from families and hospitals," Ms Thomas said.
"A big difference from a hospital is that we don't have fixed visiting hours. Family members and pets can come and visit any time.
"It is meant to be a soothing and calming environment with no bells and whistles and bustling that the hospital has."
Allison Leech, a nursing teacher at CQ University and former director of nursing at Toowoomba Hospice, believed more palliative care options were needed in regional areas as it eases the burden for both local health care systems and families.
"Many Australians want to die at home, but it's not always possible. So this becomes a home-like environment, and patients and families can do things on their own terms."
Fitzroy Hospice clinical nurse Megan Anderson saw the hospice as a place to create memories.
"It is holistic and we see the family as a key part of patient care," she said.
A Queensland Health spokesperson said hospice care was a critical part of the health care system, providing funding to some non-government organisations for palliative care services.
"Our palliative and end-of-life care strategy includes $171 million to fund more palliative care services and boost the workforce across the state," the spokesperson said.
Neil died in January this year after spending a week at the hospice.
Ms Robinson said the week was spent sitting at Neil's side with Hope, the family dog, resting her head in Neil's hand.
She said it was a "peaceful passing for Neil" and a comforting experience for the family.
"The staff provided us with everything we needed to know so we understood the dying process," Ms Robinson said.
"It was the next best thing to caring for Neil at home."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

News.com.au
2 minutes ago
- News.com.au
Health Check: Neuren says the US Rett syndrome market is a case of glass half full
Neuren's US partner Acadia reports a 14% sales boost Look out for a slew of advanced clinical trial results in early 2026 IDT Australia shares plunge up to 39% after CEO departs 'with immediate effect' Despite firming US sales of its Rett syndrome treatment Daybue, Neuren Pharmaceuticals (ASX:NEU) says two-thirds of eligible patients are yet to try the drug. Neuren's US partner Acadia Pharmaceuticals overnight reported quarterly net sales of US$96.1 million, up 14% year on year. The Nasdaq-listed Acadia says a record number of patients received a shipment, growing for the third consecutive quarter. Acadia holds the global rights to Daybue and pays royalties to Neuren, which initially developed the drug. Affecting boys, Rett syndrome is a rare neurodevelopmental disorder resulting in slow development after the ages of six to 18 months. Acadia has guided to net sales of US$380-405 million, which at the current exchange rate will generate $62-67 million of royalties for Neuren in calendar 2025. Neuren earned $14.7 million in the June quarter, up 16% year on year. By their nature, royalties are pretty much pure profit. More patients – and they're more persistent Acadia says a record 987 patients received Daybue in the quarter, up from 954 in the March quarter. Despite concerns about side effects, 50% of patients persisted after 12 months' treatment. Neuren adds that 70% of active patients have now been on therapy for 12 months or longer. This was up from 65% previously. The company says two-thirds of the 5500 to 5800 diagnosed US patients are yet to try Daybue. The FDA approved the therapy in March 2023 and Acadia expects European assent in the March 2026 quarter. Neuren shares this morning spurted as much as 8%. They've more than doubled since their mid-April trough of $8.60. Investors spoil IDT's golden jubilee Veteran contract drug maker IDT Australia's (ASX:IDT) golden jubilee has been spoiled by a savage share rout, resulting from the news that CEO Paul McDonald would depart 'with immediate effect'. The company also issued a lacklustre trading update, flagging a boost in revenue for the year to June 30, 2025, but a widening loss. A former Pfizer exec, McDonald had been in the job for almost three years. Chairman Mark Simari becomes executive chair while the company searches for a new CEO. IDT says its full-year revenue should come in at $19.9 million, a 40% increase. The company cites an increase in disbursement revenue. This derived from raw material costs and equipment charged to customers at a 'modest' margin. IDT says mainly applying to new contracts, disbursements are a 'positive lead indicator'. IDT also expects a net loss of $7.5 million, compared with a $5.4 million deficit last year. This reflects $1.2 million of bad debts from two customers defaulting on payments. Founded in 1975, IDT has had a convoluted history, including missing out on a government funded Covid vaccine plant at the last minute. These days IDT pursues gene technology, antibody drug conjugates, medical marijuana and psychedelic treatments for mental disorders. The company is in the third year of its five-year strategy, spurred by a board 'refresh' in September 2022. IDT's $30 million worth is backed by the value of the company's Boronia premises in eastern Melbourne. This hard-to-replicate is in the books at a conservative $21 million. We're on track, say drug developers Investors can look forward to a slew of company-making trial results in 2026, according to presenters at this year's Bioshares summit in Hobart. Alzheimer's disease drug developer Actinogen Medical (ASX:ACW) says it's on track to report interim results from its advanced phase IIb/III trial, by January next year. The company is enrolling 220 patients for its Xanamia trial for mild to moderate sufferers, across 15 Australian and 20 US sites. Actinogen's candidate Xanamem targets excess levels of cortisol in the brain – a novel mechanism of action. The company expects to unveil data from the first 100 patients, after 24 weeks' treatment. Final results are expected in late 2026. Stem cell developer Cynata Therapeutics (ASX:CYP) expects to release results of its phase III osteoarthritis (OA) trial between February and April next year. Cynata's mesenchymal stromal cells modulate the immune system and enable tissue repair. The OA program is the most advanced of Cynata's four trials that also cover graft-versus-host disease, diabetic foot ulcers and kidney transplants. Vitiligo is a circa US$500 million market, says Clinuvel The developer of an approved treatment for a rare sun intolerance disorder abbreviated as EPP, Clinuvel Pharmaceuticals (ASX:CUV) is advancing its proposed treatment for the more common vitiligo. The company has fully enrolled its 210 patient phase III trial, with a readout due in the June half. Affecting about 1% of the population, vitiligo is skin discolouration that results from the destruction of pigment-producing cells called melanocytes. The late Michael Jackson was a celebrity sufferer. If the drug gets US Food and Drug Administration (FDA) approval, the company estimates US$490-570 million of revenue in years one and two. Put in context, Clinuvel reported revenue of $35.6 million in the 2024 December half, up 10%. These sales derived from the company's EPP treatment, Scenesse. Doing the numbers on Imricor Broker Canaccord reckons Imricor Medical Systems (ASX:IMR) could be worth more than twice its current valuation – but faces constrained hospital budgets for the time being. In a 60-page appraisal of the cardiac ablation catheter developer, the firm estimates 120 US hospitals could be using the device within five years. Assuming 35% penetration of the ablation procedures, this equates to a $2.50 per share valuation compared with around $1.40 now. 'The big question ... is how quickly can these installs happen,' the firm says. Uniquely, Imricor's catheters are guided in real-time with magnetic resonance imaging – MRI – rather than via x-ray. The procedure is called interventional cardiac magnetic resonance cardiac ablation (ICMR CA). The company initially is focused on the US$12b arrhythmia market. Canaccord believes Imricor is still 12-18 months away from a 'material revenue ramp'. But after that it's off to the races. Imricor has an initial US target market as 120 large academic hospitals, 20 of them high volume. The firm estimates that facilities will install 190 ICMR US labs globally five years post launch. Of these, 100 will be in the US with total revenue of US$250 million. Imricor currently is undertaking a trial aimed at FDA approval for atrial flutter procedures, with a decision by the end of 2026.

News.com.au
32 minutes ago
- News.com.au
Indonesian protesters call for Australia to stop sending plastic waste as microplastic found in foetuses
Furious scenes have erupted outside an Australian embassy overseas, with protesters claiming their babies are being 'poisoned'. Environmental activists in the Indonesian city of Surabaya have demanded Australia stops sending plastic waste to Indonesia, arguing the contaminated waste has developed micro plastics in foetuses. Protesters dragged two large dolls in front of the Australian Consulate-General to depict a scene of babies engulfed by contaminated plastic waste, and a mannequin of a pregnant mother. They arrived also with masks, signs and a megaphone relaying their message. 'Australia's plastic waste is poisoning out babies,' one sign read. 'Your plastic lifestyle destroys babies' future,' another read. The news comes as Ecological Observation and Wetland Conservation (ECOTON) recently revealed Australia was the largest exporter of plastic waste to Indonesia between 2020 and 2024, sending more than 2.7 billion kilograms, according to the UN Comtrade Database. It also found more than 60 per cent of paper waste sent from Australia to Indonesia was contaminated either by flexible plastics scrap, multilayer plastic or soiled plastic packaging. Such materials cannot be recycled and end up building up at illegal dump sites. Even more concerning, in late 2014 ECOTON tested more than 80 baby care products and found nearly 60 per cent of them contained microbeads, which are tiny plastics that enter the body through the skin. 'We found that microplastics were already present in the foetus,' one protester said. 'Then our findings show they were in the placenta, meaning these small plastic particles were already able to penetrate the placenta and also the amniotic fluid. 'Now, this can be concerning for the future of this nation's life.' The move aims to put pressure on the Australian government to reconsider how it disposes of plastic waste and the impact on the Indonesian people. It's another push drawing attention to the matter that has become a big talking point Indonesia, with protests becoming almost routine. Protesters organised a similar event last year in July when the 'Your Trash Drowns Us' protest was held in the same spot outside the embassy, demanding the Australian government to stop sending plastic waste that was impacting the environment in East Java. 'I've heard of the concept of Laudato Si' from Pope Francis. Are we going there? Hopefully,' Indonesian environmentalist Prigi Arisandi said. Laudato Si', the then-pope's encyclical from 2015, stressed the international obligation to take care of the environment, with a call for ecological conversion.

ABC News
an hour ago
- ABC News
Brandy production returns to Coonawarra as winery revives distilling heritage
For the first time in decades, brandy is returning to the Coonawarra. The region was once a major producer of the wine-based liquor, before it dropped out of fashion. The idea to bring back brandy to the Coonawarra came from the director of Majella Wines, Brian "Prof" Lynn. After contemplating launching a spirit, he thought brandy would be the most natural progression from wine. It has so far been a straightforward addition for the business, requiring only a distillation still in addition to their existing wine, rainwater and wooden ageing barrels. Mr Lynn has found the distilling process to be quick, only taking about six hours. But the ageing process is slow, with all brandy legally required to be aged for two years in a wooden cask. Despite the strong historic origins of brandy in the region, Majella's release is the first to include the region on the labelling. In the early 1900s, tastes were changing and demand for dry reds dwindled. The brandy produced with the surplus grapes would eventually become generically branded brandy. But as other wine varieties grew in popularity, Coonawarra's brandy production declined and eventually stopped in the late 20th century. Much of the knowledge about Coonawarra brandy has been lost through the decades, but there are some in the region still with connections to the liquor. Coonawarra resident Diana Clayfield's father, Arthur Hoffmann, was a viticulturalist, wine and brandy maker in the region. "He enjoyed doing it [making brandy]," she said. Ms Clayfield remembers the generation before her enjoying a brandy, and sometimes even using it for medicinal purposes. "If you had a flu, they warmed brandy and wine up together and had it as a medicine," she said. It was this connection with medicine that helped brandy to become so popular, with production peaking in the 1960s. Luke McCarthy has extensively researched and written about Australian spirits and brandy. He said hospital brandy emerged around the turn of the 20th century, with major brands producing it into the 1940s. The term fell out of vogue around the same time brandy production declined. Another blow was the federal excise on brandy, facing a large increase in the 1970s to be closer to other spirits. "It's a combination of economic forces, government intervention and then shifting consumer trends, which have seen brandy really ride this sort of roller coaster ride over the last 100 years," Mr McCarthy said. Australian Distillers Association president Holly Klintworth said, although the market for other spirits like gin had become crowded, there was an opportunity ahead for brandy. "There's definitely a place in Australia for brandy and I hope that it's only a matter of time before more and more people start to rediscover just how amazing brandy can be," she said. And it could be a money spinner for wineries — Ms Klintworth's distillery turns "about $16,000 worth of wine into the equivalent of $1.5 million worth of brandy". "It makes a lot of sense. We've got so many wine regions," she said. Mr Lynn agrees that conditions are right for a comeback. He was already ageing a fresh batch of brandy to release in future years. "In the old days, brandy was huge; everyone drank brandy," he said.